ProQR Therapeutics
PRQR
50 hedge funds and large institutions have $125M invested in ProQR Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 11 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
5.06% less ownership
Funds ownership: 60.79% → 55.73% (-5.1%)
9% less funds holding
Funds holding: 55 → 50 (-5)
42% less capital invested
Capital invested by funds: $215M → $125M (-$90.2M)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.55M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.4M |
| 3 |
Renaissance Technologies
New York
|
+$675K |
| 4 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$661K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$12.6M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$4.55M |
| 3 |
ClearBridge Investments
New York
|
-$3.91M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.13M |
| 5 |
Jennison Associates
New York
|
-$1.84M |
PRQR Hedge Fund Activity: Q3 2019 in Review
50 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2019, worth a combined $125M — down 42% from $215M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of PRQR and 6 opened new positions — a net loss of 5 holders — while 12 trimmed existing stakes and 16 added.
The largest buyer was Sphera Funds Management, adding an estimated $3.55M. The largest seller was OrbiMed, exiting entirely with an estimated $12.6M sold.
- 50 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2019, down from 55 in Q2 2019.
- Funds reported $125M of ProQR Therapeutics stock for Q3 2019, down 42% quarter-over-quarter.
- 6 funds opened new ProQR Therapeutics positions in Q3 2019 and 11 closed out, a net change of -5 holders.
- The largest ProQR Therapeutics buyer in Q3 2019 was Sphera Funds Management, an estimated $3.55M added.
- The largest ProQR Therapeutics seller in Q3 2019 was OrbiMed, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2019.